EN
R&D Pipeline
our company utilizes four major platforms, including gene editing technology, to develop a pipeline of products such as gene-edited T cells, NK cells, and stem cells. These product lines primarily focus on cancers and age-related degenerative diseases. Currently, the "PD-1 Gene-Edited T Cell Injection" has received approval for IND as a Class I cellular new drug from the National Medical Products Administration in January 2024.
